Table 2.
Adverse Events of Interest | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 |
---|---|---|---|---|---|
Cytokine Release Syndrome | |||||
SCRI-CAR19v1 (n=43) | 39.5% (17) |
48.8% (21) |
4.7% (2) |
0 | 0 |
SCRI-CAR19v2 (n=21) | 19% (4) |
57% (12) |
0 | 0 | 0 |
Neurotoxicity | |||||
SCRI-CAR19v1 (n=43) | 14% (6) |
16% (7) |
9% (4) |
9% (4) |
0 |
SCRI-CAR19v2 (n=21) | 0 | 14% (3) |
10% (2) |
10% (2) |
5% (1) |